Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Time to Reperfusion Determines Clinical Outcomes Independent of Post Thrombectomy Infarct volume
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease and Interventional Neurology Posters (7:00 AM-5:00 PM)
042
To investigate whether early (<6-hours) recanalization of large vessel occlusion (LVO) stroke leads to superior functional outcomes compared to delayed recanalization (>6-hours) amongst patients with similar 24-hour infarct volumes post thrombectomy
Outcomes post thrombectomy are time-dependent and are partly a function of final infarct volume.However, late time-window thrombectomy trials demonstrated that good functional outcomes can be achieved up to 24 hours from stroke onset in Slow Progressors (small infarct volume, large penumbral volume). The impact of time to recanalization on outcomes in Slow Progressors is unknown. 

A retrospective analysis of a prospectively maintained thrombectomy database across 3 centers. Demographic, clinical, and outcomes data were analyzed. Inclusion criteria were witnessed onset LVO [internal carotid/middle cerebral artery-M1] strokes with baseline mRS score 0-1 having achieved mTICI 2b-3 recanalization and 24-hour infarct volume of ≤10 ml on CT head/MRI. Multivariate analysis of the impact of time to recanalization on outcomes was performed.

 

Of 499 LVO strokes undergoing thrombectomy, 30% (148) met criteria. Mean age was 70 ±14 and median NIHSS was 17 (14-21). Early recanalization (<6h) was achieved in 65% (96) of patients. Baseline demographic (age: 73 vs 74,p=0.80)  and clinical characteristics (NIHSS:16.5 vs 17,p=0.52; 24-h infarct volume: 4.4 vs 4.2 ml,p=0.60) were comparable between early versus late recanalizers. Rates of early clinical improvement (24-h NIHSS <6) (71% vs 39%,p=0.0007) and 90-day mRS 0-2 (68% vs 48%,p=0.019) were higher in early recanalizers. Early recanalization was an independent predictor of 90-day mRS 0-2 (OR-2.41 95%-CI 1.89-4.50). Every 1-hour increase in time to recanalization decreased the odds of 90-day mRS 0-2 by 2.2%.

 

Among patients with similar 24-hour infarct volume post thrombectomy (≤10 ml), shorter time to successful recanalization is associated with significantly higher rates of early clinical improvement and 90-day mRS 0-2. Increased penumbral ischemic time may have an impact on outcomes post thrombectomy.

Authors/Disclosures
Shashvat Desai, MD (University of Pittsburgh Medical Center)
PRESENTER
Dr. Desai has nothing to disclose.
Amin Aghaebrahim, MD Dr. Aghaebrahim has nothing to disclose.
James E. Siegler III, MD (University of Chicago) Dr. Siegler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Siegler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer. Dr. Siegler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Serb. Dr. Siegler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Siegler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Wallaby Phenox. Dr. Siegler has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Stroke: Vascular and Interventional Neurology. Dr. Siegler has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Precision Medicine, LLC. The institution of Dr. Siegler has received research support from Philips. The institution of Dr. Siegler has received research support from Medtronic.
No disclosure on file
Ashutosh P. Jadhav, MD, FÂé¶¹´«Ã½Ó³»­ (Barrow Neurological Institute) Dr. Jadhav has nothing to disclose.
Tudor G. Jovin, MD (Cooper University Healthcare) Dr. Jovin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerenovus. Dr. Jovin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Contego Medical. Dr. Jovin has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Several law firms. Dr. Jovin has stock in Corindus. Dr. Jovin has stock in Methinks. Dr. Jovin has stock in Viz.ai. Dr. Jovin has stock in Route92. Dr. Jovin has stock in FreeOx Biotech. Dr. Jovin has stock in Galaxy. Dr. Jovin has stock in Kandu. The institution of Dr. Jovin has received research support from Stryker. The institution of Dr. Jovin has received research support from Medtronic.